Lutando contra a pandemia COVID-19
Por trás de cada laboratório está o apoio de 53.000 Healthineers

Processamento do vírus SARS-CoV-2

A urgência e a complexidade da situação atual do COVID-19 continuam a crescer e impactando profundamente todo o mundo e os laboratórios desempenham um papel essencial nisso tudo. Os testes para SARS-CoV-2 não são a única necessidade no tratamento de pacientes com COVID-19. A Triagem e monitoramento ágeis e precisos também são necessários para a variedade de problemas de saúde que podem surgir como parte da doença COVID-19.

O papel essencial do diagnóstico laboratorial na infecção por SARS-CoV-2

 

Estamos empenhados em auxiliar os laboratórios a enfrentar este novo cenário, a fim de ajudá-los a prestar o melhor atendimento aos pacientes neste momento desafiador. Nosso Guia de Teste de Laboratório COVID-19 fornece conteúdo oportuno e relevante para apoiar o papel estendido dos diagnósticos de laboratório no gerenciamento de pacientes com COVID-19:

  • Transmissão e classificação clínica
  • Curso de pacientes em risco
  • Recomendações atuais para testes de laboratório
  • Anormalidades laboratoriais frequentes
  • Impacto de pacientes com comorbidades

Na Siemens Healthineers, estamos totalmente comprometidos em apoiar nossos parceiros em todo o sistema de saúde, ajudando-os a oferecer assistência de alto valor aos pacientes.

 


Teste de diagnóstico para COVID-19

Como um patógeno humano verdadeiramente emergente, um teste específico para a presença do vírus não existia no início dos casos, necessitando de desenvolvimento rápido. A maioria dos testes atuais para infecção depende da detecção do RNA viral usando uma reação em cadeia da polimerase com transcrição reversa (rtPCR). Além disso, o teste sorológico de uma amostra de sangue pode identificar anticorpos para o vírus. 1,2 Esses testes provavelmente serão extremamente valiosos para a vigilância e podem potencialmente fornecer avaliação da imunidade, além de ajudar na identificação de infecção aguda.
À medida que a disponibilidade e os suprimentos para testes moleculares para COVID-19 aumentam, os tempos de resposta dos testes devem melhorar, mas permanecem dependentes da coleta de amostras, do manuseio pré-analítico adequado (o RNA é altamente degradável), do tempo para o resultado do teste e do acesso ao teste (pontual). atendimento versus laboratório).
 

Webinar patrocinado pela AACC


AACC Webinar: Cytokine Storm Syndrome and COVID-19

In this webinar, Dr. Randy Cron will discuss criteria for identifying Cytokine storm syndrome (CSS) in patients, complications, and available treatments which include glucocorticoids, but also targeted therapies that dampen pro-inflammatory cytokines like interleukin-1 (IL-1) and IL-6.

Speaker:
Randy Q. Cron, MD, PhD
University of Alabama at Birmingham

Watch the webinar today

O Papel do Diagnóstico Laboratorial na Infecção por SARS-CoV-2 e Comorbidades Relacionadas

 Experiências e estratégias de gerenciamento populacional de regiões altamente afetadas da China e da Itália: os testes de laboratório são vitais em várias vias clínicas e este webinar descreve como a medicina de laboratório pode ajudar eficientemente a combater o surto de COVID-19. 

Speakers:
Prof. Mario Plebani
Professor de Bioquímica Clínica e Biologia Molecular Clínica, Faculdade de Medicina da Universidade de Padova
Chefe, Departamento de Medicina Laboratorial, Hospital Universitário, Pádua, Itália

Prof. Shu Kui Wang
Vice-reitor
Diretor do Laboratório Central
Primeiro Hospital de Nanjing, Universidade Médica de Nanjing, Nanjing, China

 

Assista ao webinar hoje

GALLERY: Infographics to learn about COVID-19 Testing

COVID-19 Testing Infographic 2020

Testing is key to reopening communities, businesses, and the economy

Combined testing to detect the virus and antibodies that may protect against it is essential to safely return employees to work.
Get the infographic here
Total Assay Infographic lab version

SARS-CoV-2 Total Assay1

Secure your community with science and scale
Download the infographic
Total Assay Infographic media version

Not all antibody tests are created equal

High quality, extensive reach and targeting the right protein are all essential to ensure we effectively manage the threat of COVID-19
Download the infographic
COVID-19 infographic

Clinical information for laboratorians

Learn about diagnosis and treatment of COVID-19 patients
Download the infographic
CytokineStorm Infographic

Staying ahead of cytokine storm syndrome

Gain important knowledge about cytokine storm syndrome and COVID-19
Download Infographic
Specificty Matters Infographic

Why Specificity Matters in COVID-19 antibody testing

Test quality and accuracy are paramount to minimize risks of inaccurate results. A good antibody test is one that has a high degree of sensitivity and specificity.
Get the infographic here
Lab testing and frequent laboratory abnormalities in patients with COVID-19 infographic

The essential role of laboratory diagnostics

Lab testing and frequent laboratory abnormalities in patients with COVID-19
Download the infographic

COVID-19 Laboratory Testing Guide

Testing is critical to differentiate COVID-19 from other respiratory disease such as influenza or RSV (respiratory syncytial virus). Widespread testing will both inform a COVID-19 diagnosis and aid a greater understanding of disease prevalence, especially in infections that are asymptomatic.

Download the COVID-19 Laboratory Testing Guide

COVID-19 Booklet

  • What are the symptoms of COVID-19?
  • How does COVID-19 progress?
  • How to test for, treat, and immunize
  • How are COVID-19 tests administered?
  • How to avoid spreading COVID-19
Download the COVID-19 Booklet

Download eBook: Coagulation abnormalities in COVID-19 patients

As part of our commitment to labs and clinicians in the fight against the pandemic, we aim to keep you informed on current coagulation testing and monitoring recommendations in COVID-19 patients. Read our eBook for an overview on:

  • Thrombosis risk factors
  • ISTH-recommended coagulation testing algorithm
  • Leading recommendations for anticoagulation treatment
  • Relevant parameters for patient monitoring
Download the eBook

AACC Webinar: Cytokine Storm Syndrome and COVID-19

In this webinar, Dr. Randy Cron will discuss criteria for identifying Cytokine storm syndrome (CSS) in patients, complications, and available treatments which include glucocorticoids, but also targeted therapies that dampen pro-inflammatory cytokines like interleukin-1 (IL-1) and IL-6.

Speaker:
Randy Q. Cron, MD, PhD
University of Alabama at Birmingham


Compartilhe esta página:

The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.

1. Ehterinton, D. https://techcrunch.com/2020/03/27/the-fda-just-okayed-multiple-15-minute-blood-tests-to-screen-for-coronavirus-but-there-are-caveats/ (Accessed March 28, 2020)

2. Morris, A. https://www.azcentral.com/story/news/local/arizona-health/2020/03/28/university-arizona-working-tests-detect-covid-19-antibodies/5083093002/ (Accessed March 28, 2020)

*Under development. Not available for sale. Future availability cannot be guaranteed.

**CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S. Pursuing FDA emergency use authorization (EUA) and WHO emergency use listing (EUL).

***This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.